Cancer Immunotherapy | CHOP Research Institute
 

Cancer Immunotherapy

Evan Weber, PhD
Evan W. Weber

Dr. Weber is developing approaches to enhance CAR-T cell therapies for pediatric cancer by reprogramming T cells with improved durability and exhaustion resistance. His work will uncover molecular mechanisms that promote CAR-T cell exhaustion and identify new targets for therapeutic intervention.

E-mail:
weberew [at] chop.edu

Center for the Investigation of Factor FVIII Immunogenicity

Center for the Investigation of Factor FVIII Immunogenicity

Revealing new mechanistic insights into the multiple facets of why factor VIII inhibitors form as an immune response to protein replacement therapy to treat hemophilia A.

Yi Xing, PhD
Yi Xing

Dr. Xing is the Executive Director of the Department of Biomedical and Health Informatics, the Francis West Lewis Chair and director of the Center for Computational and Genomic Medicine at CHOP, and professor of Pathology and Laboratory Medicine at the University of Pennsylvania. His research focuses on computational biology and genomics of RNA processing and regulation.

E-mail:
xingyi [at] chop.edu

New FVIII Center Crosses Disciplines to Reach Answers for Hemophilia A

Published on
Aug 8, 2018
in Cornerstone Blog
Valder Arruda, MD, PhD
New FVIII Center has four projects under way from diverse perspectives to find novel approaches for therapeutic intervention in hemophilia A.

Research Heroes: From Baking to Biomedicine - Nick Pautler Won't Let ALL Define Him

Published on
Oct 9, 2017
in Cornerstone Blog
Nick Pautler
Nick Pautler, a biomedical engineering student at the University of Delaware, can tell you how a lot of things work - from the microbial science behind baking sourdough bread, to the intricacy of model railroads, to the way that an army of re-engineered T-cells worked hard to fight the cancer cells in his body this past year.

CAR-T Cell Approval, Hope on Wheels, Task Force on Pregnant Women, Taking Flight for Autism, NFL Concussion Research, Doug Wallace

Published on
Sep 8, 2017
in Cornerstone Blog
CHOP Research In the News
September marks National Childhood Cancer Awareness Month, and this year at Children's Hospital of Philadelphia, we kick-started the commemorative period on the heels of exciting news about breakthroughs in pediatric cancer immunotherapy research.

CSO Perspectives: A Moment to Remember: First-of-its-Kind Cancer Treatment Approved by FDA

Published on
Aug 31, 2017
in Cornerstone Blog
Bryan A. Wolf
It was a pivotal moment that has turned into a new era for cancer immunotherapy. On April 17, 2012, Children's Hospital of Philadelphia researchers for the first time treated a pediatric patient with a cellular therapy that used her own reprogrammed immune cells, called T cells, to attack her aggressive form of blood cancer.